A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1s—medications containing the same active ingredients as the blockbuster weight-loss drugs but sold at a much lower price.

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News has established. Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.